Octopus Group

ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology

Retrieved on: 
Mercredi, mai 29, 2024
Other Science, Pharmaceutical, Research, Artificial Intelligence, Oncology, Software, Infectious Diseases, Genetics, Data Management, Stem Cells, Science, Technology, Clinical Trials, Cardiology, FDA, Biotechnology, Agriculture, Natural Resources, Health, Intron, DNA, University, Gene expression, Toxicity, Machine learning, Algorithm, AI, Growth, Octopus Group, Genome, Tissue, Gene, A-DNA, Therapy, Multimedia, Vaccine

ExpressionEdits , a biotechnology company optimizing protein expression using AI and proprietary intronization technology, announced today a $13 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.

Key Points: 
  • ExpressionEdits , a biotechnology company optimizing protein expression using AI and proprietary intronization technology, announced today a $13 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
  • By strategically incorporating multiple short noncoding DNA sequences known as introns into artificial genes, ExpressionEdits has achieved significant enhancements in gene expression which leads to better protein production.
  • “At ExpressionEdits, we're revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production,” said Dr. Kärt Tomberg, CEO & Co-Founder, ExpressionEdits.
  • “Their proprietary intronization technology unlocks the capacity to express highly complex molecules previously deemed unattainable, while regulating them with precision.

Dion Cornett Joins Tatum as Chief Executive Officer

Retrieved on: 
Mardi, mai 7, 2024
Northwestern University, Octopus Group, United States Naval Academy, Red Hat, MBA, Software, MariaDB, Web3, Kellogg School, Growth, DBeaver

LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.
  • Dion brings to Tatum two decades of experience in the software industry and an exceptional track record in successfully scaling businesses through product led growth.
  • Dion Cornett is recognized as an expert in open-source software and database technologies, having held senior leadership positions at Red Hat, MariaDB, ReachForce, Liquibase and DBeaver.
  • "I am excited to join Tatum and work with a talented team that is passionate about leveraging blockchain technology to redefine our digital future," said Dion Cornett.

Dion Cornett Joins Tatum as Chief Executive Officer

Retrieved on: 
Mardi, mai 7, 2024
Northwestern University, Octopus Group, United States Naval Academy, Red Hat, MBA, Software, MariaDB, Web3, Kellogg School, Growth, DBeaver

LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.
  • Dion brings to Tatum two decades of experience in the software industry and an exceptional track record in successfully scaling businesses through product led growth.
  • Dion Cornett is recognized as an expert in open-source software and database technologies, having held senior leadership positions at Red Hat, MariaDB, ReachForce, Liquibase and DBeaver.
  • "I am excited to join Tatum and work with a talented team that is passionate about leveraging blockchain technology to redefine our digital future," said Dion Cornett.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Jeudi, mai 2, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Mardi, avril 30, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, April 30, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Pelago Announces $58 Million Series C Funding to Strengthen Leadership in Substance Use Management

Retrieved on: 
Jeudi, mars 28, 2024
Mental Health, Mobile, Wireless, Technology, Hospitals, Telemedicine, Virtual Medicine, Software, Internet, Managed Care, General Health, Health, Factitious disorder, ROI, Growth, Y Combinator, Partnership, Suds, Research, Atomico, Human, Live Nation Entertainment, Octopus Group, Tobacco, Kinnevik AB, Absenteeism, Life, WTW, Series, Multimedia, Pharmaceutical industry

Pelago , the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced $58 million in new funding on the strength of customer growth and validated ROI, bringing total funding to $151 million.

Key Points: 
  • Pelago , the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced $58 million in new funding on the strength of customer growth and validated ROI, bringing total funding to $151 million.
  • View the full release here: https://www.businesswire.com/news/home/20240328996003/en/
    The additional capital raised will help Pelago accelerate its product roadmap, extend its continuum of care and advance clinical research efforts.
  • As part of this latest round, Atomico Partner Laura Connell will join the Pelago board.
  • “I’m so proud of the work we have done to improve lives and expand access to substance use care that works.

Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline

Retrieved on: 
Mercredi, avril 3, 2024
Lung cancer, LBA, Conference, Growth, NSCLC, Partnership, Patient, NGS, Biomarker, Research, Octopus Group, Laboratory, Medicine, AACR, Agilent Technologies, Pharmaceutical industry

Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.

Key Points: 
  • Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.
  • "This significant investment underlines the confidence of our investors in Biofidelity's unique technologies and our mission to bring the benefits of precision medicine to all patients," said Biofidelity Co-Founder and CEO Dr. Barnaby Balmforth.
  • The new funding round includes fresh commitments from current investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
  • "We are thrilled to continue our partnership with Biofidelity as the team embarks on the next phase of their growth and commercial expansion."

HR Solution Remofirst Raises $25 Million Series A Funding to Make it Affordable and Easy to Employ Global Remote Teams

Retrieved on: 
Mercredi, mars 6, 2024
Software, Technology, Professional Services, Human Resources, QED, Octopus Group, Multimedia, Volodymyr, Mastercard, World Health Organization, Organization, Tax, Zocdoc, Organizational founder, Cryptocurrency

View the full release here: https://www.businesswire.com/news/home/20240306357812/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306357812/en/
    Remofirst cofounders Nurasyl Serik (left) and Volodymyr Fedoriv, who saw a need for a simple and affordable way for companies to legally and compliantly employ global teams, today announced $25 million in Series A venture capital funding.
  • This additional funding is a huge milestone for Remofirst, validating its vision for the future of global distributed teams and our superior solution that is affordable and easy to use.
  • The Remofirst solution leverages local in-country legal experts to ensure that its contracts are compliant in all locations, avoiding misclassification risks.
  • Prior to its Series A round, Remofirst raised $14.1 million in Seed funding in 2022.

Gen-Z Favorite Photo-Sharing App Lapse Closes $30 Million in Series A Funding to Build a New Kind of Social Media

Retrieved on: 
Mardi, février 27, 2024
Engineering, GV (company), Social media, Roblox, Octopus Group, Snap Inc., GV, General partnership, Friends, Science, Pinterest, Camera

The raise validates a year of exponential growth for Lapse, which became the most downloaded app in the Apple US & UK app stores.

Key Points: 
  • The raise validates a year of exponential growth for Lapse, which became the most downloaded app in the Apple US & UK app stores.
  • As Lapse has grown, Co-founders Ben and Dan have prioritized evolving the app to meet the needs of its community.
  • We've only scratched the surface of our grander vision: To build a new kind of social media," says Co-founder Dan Silvertown.
  • For more information about Lapse and its pioneering approach to capturing and sharing photos, please visit lapse.com .

Gen-Z Favorite Photo-Sharing App Lapse Closes $30 Million in Series A Funding to Build a New Kind of Social Media

Retrieved on: 
Mardi, février 27, 2024
Engineering, GV (company), Social media, Roblox, Octopus Group, Snap Inc., GV, General partnership, Friends, Science, Pinterest, Camera

The raise validates a year of exponential growth for Lapse, which became the most downloaded app in the Apple US & UK app stores.

Key Points: 
  • The raise validates a year of exponential growth for Lapse, which became the most downloaded app in the Apple US & UK app stores.
  • As Lapse has grown, Co-founders Ben and Dan have prioritized evolving the app to meet the needs of its community.
  • We've only scratched the surface of our grander vision: To build a new kind of social media," says Co-founder Dan Silvertown.
  • For more information about Lapse and its pioneering approach to capturing and sharing photos, please visit lapse.com .